Company: STAA
Filing Date: 2025-12-02
Form Type: DFAN14A
Source: 0001213900-25-117366
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-12-02
Form: DFAN14A
Chunk 2
---
ETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some
or all of the Company’s stockholders and will be, along with other relevant documents, available at no charge on the SEC’s
website at https://www.sec.gov/.

Information about the Participants and a description
of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants
with the SEC on November 21, 2025 and is available here.

Exhibit 1

<div align='center'>Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors

Pursuing Board Changes to Restore Investor Confidence and Ensure Integrity of Ongoing Sale Process

Broadwood Seeks to Remove the Directors Most Responsible for the Flawed Sale Process: Board Chair Elizabeth Yeu, CEO Stephen Farrell, and Compensation Committee Chair Arthur Butcher</div>

New York – (BUSINESS WIRE) – Broadwood
Partners, L.P. and its affiliates (collectively, “Broadwood”) today announced that it is well along in the multi-step and
time-consuming process that is required to call a Special Meeting of Shareholders (the “Special Meeting”) at STAAR Surgical
Company (“STAAR” or the “Company”) (NASDAQ: STAA) to remove three directors from the Company’s Board of
Directors (the “Board”). Broadwood, which owns 30.2% of STAAR’s outstanding common stock, continues to oppose the current
agreement to sell the Company to Alcon Inc. (“Alcon”) (NYSE: ALC), and believes changes to STAAR’s Board are needed
to restore investor confidence in the Board’s decision making and the sale process.

At the Special Meeting, Broadwood intends to seek the removal of the
three incumbent directors it believes are most responsible for incentivizing, facilitating, and promoting the sale of the Company to Alcon
at the wrong time, after a flawed process, and at an inadequate price:

| ● | Elizabeth Yeu, STAAR’s Board Chair, whose close and longstanding relationship with Alcon — which does not appear                
 to have been disclosed to the full Board or to shareholders in a timely manner — may have caused her to ignore inbound interest 
 from another prospective acquirer and, in so doing, irredeemably